Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Sponsor
Xuanwu Hospital, Beijing
Study ID
NCT06140732
Phase
PHASE2
Status
Unknown

Conditions

  • Chemotherapy Effect
  • Chordoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date
Oct 30, 2023
Status verified
Oct 2023
Primary completion
Jan 1, 2025
Completion
Jan 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab combined with apatinib
    camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd

Primary Outcome Measure

Effectiveness: Progression-free survival (PFS) [ Time Frame: 6 months ]

Central Contacts

Related Studies